An inhibitor of wild-type and mutant EGFR and HER2
此产品仅用于科学研究,我们不为任何个人用途提供产品和服务
BDTX-189 is an inhibitor of wild-type and mutant EGFR and HER2 (IC50s = ≤30-500 and ≤10-100 nM, respectively).1 In vivo, BDTX-189 (30 and 50 mg/kg, twice daily) reduces tumor growth in a CUTO14 non-small cell lung cancer (NSCLC) mouse xenograft model.
1.Flohr, A., Mayweg, A., Trainor, G., et al.Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use(2020)
没有评价数据